Syndicate content The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
Updated: 12 min 8 sec ago

Vascular Pathways, Inc. Signs New Agreement With Amerinet for AccuCath(R) Line of Catheters

Thu, 02/05/2015 - 15:44
BOCA RATON, FL--(Healthcare Sales & Marketing Network) - Vascular Pathways, Inc., a privately held medical device manufacturer with innovative wire guided technology for peripheral intravascular access, today announced a new agreement with Amerinet, a nati...
Devices, Group Purchasing
Vascular Pathways, Amerinet, AccuCath

Hansen Medical Announces Expanded Protocol for the ARTISAN AF IDE Study

Thu, 02/05/2015 - 15:41
FDA Approves Inclusion of the Latest Technology for the Treatment of Atrial Fibrillation MOUNTAIN VIEW, CA--(Healthcare Sales & Marketing Network) - Hansen Medical, Inc. (NASDAQ: HNSN), a global leader in intravascular robotics, today announced FDA appr...
Devices, Cardiology, FDA
Hansen Medical, Sensei, Robotic Catheter, atrial fibrillation

First TomoTherapy(R) System in Latin America Dedicated Solely to Breast Cancer Care Now Treating Patients

Wed, 02/04/2015 - 13:50
Advanced Radiation Therapy System Ideally Suited for Efficient, Effective Treatment of Range of Breast Cancer Cases SUNNYVALE, Calif., Feb. 4, 2015 -- (Healthcare Sales & Marketing Network) -- Accuray Incorporated (ARAY) announced today that the first ...
Devices, Radiology, Oncology
Accuray, TomoTherapy, radiotherapy, IMRT, TomoHelical

Third Rock Ventures Launches REVOLUTION Medicines with $45 Million Series A to Redesign Evolution’s Products to Treat Serious Diseases

Wed, 02/04/2015 - 13:44
Company Secures Exclusive License Agreement with University of Illinois SAN FRANCISCO/REDWOOD CITY, Calif.--(Healthcare Sales & Marketing Network)--Third Rock Ventures, LLC today announced the formation of REVOLUTION Medicines, Inc. with a $45 million S...
Biopharmaceuticals, Venture Capital

Concert Pharmaceuticals Announces Appointment of James V. Cassella as Chief Development Officer

Wed, 02/04/2015 - 13:38
LEXINGTON, Mass.--(Healthcare Sales & Marketing Network)--Concert Pharmaceuticals, Inc. (CNCE) today announced that it has appointed James V. Cassella, Ph.D. as Chief Development Officer. In this newly created role, Dr. Cassella will lead Concert’s product...
Biopharmaceuticals, Personnel
Concert Pharmaceuticals

Mazor Robotics Names Sandra Adzic Vice President of International Sales

Wed, 02/04/2015 - 13:32
CAESAREA, Israel--(Healthcare Sales & Marketing Network)--Mazor Robotics Ltd. (TASE:MZOR; NASDAQGM:MZOR), a developer of innovative guidance systems and complementary products, today announced that Sandra Adzic has been named Vice President of Internationa...
Devices, Surgery, Personnel
Mazor Robotics, Renaissance, robotic surgery

Genentech’s Phase III Study of Gazyva(R) Showed Significant Benefit in Refractory Indolent Non-Hodgkin’s Lymphoma

Wed, 02/04/2015 - 13:23
SOUTH SAN FRANCISCO, Calif.--(Healthcare Sales & Marketing Network)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive results from the Phase III GADOLIN study, which evaluated treatment options for people with i...
Biopharmaceuticals, Oncology
Genentech, Roche Group, GADOLIN study, Gazyva, obinutuzumab

SpineGuard Receives FDA Clearance to Market Its PediGuard Products for Minimally Invasive Surgery (MIS)

Tue, 02/03/2015 - 20:31
PARIS & SAN FRANCISCO--(Healthcare Sales & Marketing Network)--SpineGuard (FR0011464452 – ALSGD) announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its PediGuard products for Minimally Invasive ...
Devices, Orthopaedic, Neurosurgery, FDA
SpineGuard, PediGuard, pedicle screw

Guardant Health Secures Additional $50 Million Based On Strong Demand For Its Biopsy-Free Cancer Blood Test, Guardant360(R)

Tue, 02/03/2015 - 13:32
The enhanced Guardant360 now identifies all classes of actionable tumor genomic alterations with a single blood test REDWOOD CITY, Calif., Feb. 3, 2015 -- (Healthcare Sales & Marketing Network) -- Guardant Health today announced the completion of its S...
Diagnostics, Oncology, Venture Capital
Guardant Health, Guardant360, biopsy-free cancer test, liquid biopsy

U.S. FDA Grants Priority Review for YONDELIS(R) (trabectedin) for the Treatment of Patients with Advanced Soft Tissue Sarcoma

Tue, 02/03/2015 - 13:21
RARITAN, N.J., Feb. 3, 2015 -- (Healthcare Sales & Marketing Network) -- Janssen Research & Development, LLC (Janssen) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for YOND...
Biopharmaceuticals, Oncology
Janssen Research & Development, YONDELIS, trabectedin, liposarcoma

CTI BioPharma Announces Independent DMC Recommendation to Continue GOG-0212 Phase 3 Study of OPAXIO(TM) as Maintenance Therapy in Ovarian Cancer, an NRG Oncology/GOG Study

Tue, 02/03/2015 - 13:11
SEATTLE, Feb. 3, 2015 -- (Healthcare Sales & Marketing Network) -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced that the Gynecologic Oncology Group, now part of NRG Oncology, informed CTI BioPharma that an independent Data Mo...
Biopharmaceuticals, Oncology
CTI BioPharma, OPAXIO, ovarian cancer, paclitaxel poliglumex

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong